“The goal is to develop life-saving medications for patients faster. That comes down to saving time and money,” said Bonne ...

Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, discusses challenges such as high costs and long ...

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses how EDC and EHR data can be streamlined to ...

Phase III HELIOS-B trial found that Amvuttra (vutrisiran) also preserved functional capacity and quality of life in patients ...

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of ...

In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...

In 2025, sponsors will prioritize contract research organizations (CROs) offering complete and continuous data transparency ...

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses historical challenges with long protocol ...